

Special Issue

Immune Ontogeny and Vaccination in Early Life

Message from the Guest Editors

The development of the immune system needs a number of changes that occur during the first years of life. The neonatal immune system is exposed to a large number of previously unseen antigens. The field is still lacking a good animal model to get insights into immune ontogeny in early life and development of immune-mediated diseases later in life. We are currently establishing a pediatric immunology program (PIP) where the NHP will be essential and central to developing comprehensive studies that will explore immune ontogeny, microbiome, vaccination, transfer of maternal immunology, system immunology, and serology. The goal of this Research Topic is to gather several known experts in the field of pediatric immunology, infectious diseases, and vaccinology to give an update on their latest research studies that are relevant to early life newborns and immune-mediated diseases later in life, and to develop a method to use the NHP model in the most comprehensive way to address important/remaining questions in the field.

Guest Editors

Dr. Nabila Seddiki

Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases, UMR1184, IDMIT Department, Université Paris-Saclay, Inserm, CEA, 92265 Fontenay-aux-Roses, France

Prof. Dr. Roger Le Grand

Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases, UMR1184, IDMIT Department, Université Paris-Saclay, Inserm, CEA, France

Deadline for manuscript submissions

closed (10 February 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/49656

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).